A detailed July 2025 report highlights that FDA-approved biosimilars have generated $56.2 billion in savings since 2015 but face uneven market adoption across therapeutic areas. Despite potential discounts exceeding 80%, pharmacy benefit managers often favor expensive brand-name drugs on formularies, limiting biosimilar market penetration. Pipeline gaps threaten future biosimilar development, with only 12 of 118 biologics losing exclusivity by 2034 currently having biosimilars in development. Experts call for coordinated stakeholder actions to bridge this biosimilar void and improve patient access to affordable biologics.